Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

OPDIVO® (nivolumab) in combination with platinum-doublet chemotherapy, is indicated for neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung ...

Ono Pharma, Bristol-Myers & Kyowa Hakko Kirin enter pact to condutct phase 1 combo study with Opdivo & mogamulizumab in advanced solid tumors: Tokyo Friday, December 12, 2014, 11: ...

Patients with kidney cancer brain metastases have a poor prognosis and have been excluded from most clinical trials of ...

Patients with advanced melanoma who received fecal microbiota transplants using healthy donor stool alongside standard immunotherapy survived more than four years, according to final results from an ...

DelveInsight's Oropharyngeal Cancer Market Insights report includes a comprehensive understanding of current treatment ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a value of USD 294.4 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8 ...

The going has been good for Bristol Myers Squibb BMY over the past month. Shares of this biotech giant have gained 7.2% in a ...

Oct 7 (Reuters) - Bristol Myers Squibb Co (BMY.N), opens new tab said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease ...

Bristol Myers Squibb’s BMY growth portfolio put up a strong performance in the third quarter of 2025 and enabled it to offset ...

Bristol Myers’ BMY growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. Among these, immuno-oncology drug ...